- About Us
- Nano-Social Network
- Nano Consulting
- My Account
NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced today that it has elected to its Board of Directors, Gabriel Leung, President, Oncology, at OSI Pharmaceuticals, a leading biotechnology company and maker of Tarceva(R).
"We are extremely pleased to have attracted an executive of Gabe's
caliber to the Board," said Stephen Benoit, NanoMed's President and CEO,
and Patrick G. Morand, NanoMed's Chairman and Managing Director, SWMF Life
Science Fund, the company's lead investor. "There is no question that he
will play a critical role in helping us to build our drug pipeline," Benoit
added. NanoMed's lead product is a nanoparticle formulation of an
FDA-approved cancer drug used to treat adults diagnosed with acute myeloid
leukemia. This lead product is expected to enter human clinical trials in
Before joining OSI, Mr. Leung was Group Vice President, Global
Prescription Business at Pharmacia, where he served on the CEO's Operating
Committee and headed up the company's Oncology Franchise with business and
medical affairs operations in over 80 countries. Mr. Leung also oversaw all
the oncology research and development projects and portfolio strategies as
the co-chair of Pharmacia's Oncology Development Committee. During his
4-year tenure at Pharmacia, which ended with the acquisition by Pfizer, Mr.
Leung doubled the size of the oncology business to $1.3 billion in
revenues, building it into one of the then largest oncology therapeutic
companies in the world. He orchestrated two new product launches and helped
build one of the strongest oncology pipelines in the industry through
acquisition and in- licensing. Mr. Leung began his career in the
pharmaceutical industry at Eastman Pharmaceuticals/Sterling Drug Inc., and
then had a distinguished career at Bristol-Myers Squibb working on
blockbuster products including Pravachol(R), Taxol(R), and Paraplatin(R).
"NanoMed is an exciting emerging specialty pharmaceutical company with
a promising nanoparticulate formulation technology that can be leveraged to
develop a broad pipeline of pharmaceutical products for use in oncology and
many other therapeutic areas," said Mr. Leung. "I am pleased to have the
opportunity to help them grow as a member of the company's Board."
Mr. Leung is a pharmacist, trained at the University of Texas at Austin
where he earned his pharmacy degree with High Honors. Following some years
of practice in the hospital environment, Mr. Leung earned his M.S. degree
at the University of Wisconsin-Madison with concentration in pharmaceutical
marketing. Mr. Leung is a member of the National Cancer Institute Clinical
Trial Advisory Committee and is the founding chairman of the Life Sciences
Consortium, an initiative of the CEO Roundtable on Cancer. He is also an
active member and a member of the Nominating Committee of C-Change
( http://www.cchangetogether.org ), a national initiative chaired by former
President George Bush and Mrs. Barbara Bush with the goal of eliminating
cancer as a major public health problem at the earliest possible time.
About NanoMed Pharmaceuticals, Inc.
NanoMed Pharmaceuticals(R), Inc. ( http://www.nanomedpharm.com ) is an
early-stage specialty pharmaceutical company dedicated to developing
improved therapeutic and diagnostic products to treat or detect cancer and
other serious diseases. The company's lead product is a nanoparticle
formulation of an FDA-approved cancer drug used to treat adults diagnosed
with acute myeloid leukemia. This lead product is being developed using
Nanotemplate Engineering, the company's proprietary nanoparticle
manufacturing technology used to formulate small molecules, peptides,
proteins, plasmid DNA, and diagnostic agents. NanoMed is headquartered in
For more information, please click here
President & CEO
NanoMed Pharmaceuticals, Inc.
7107 Elm Valley Drive, Room B1210
Kalamazoo, Michigan 49009 USA
T - (269) 488-8525
F - (269) 488-8544
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017